EMA to Quickly Review Lilly, Incyte Arthritis Drug for COVID Use EMA to Quickly Review Lilly, Incyte Arthritis Drug for COVID Use
The European Medicines Agency will conduct an accelerated review of Eli Lilly ' s rheumatoid arthritis drug Olumiant for hospitalized COVID-19 patients getting oxygen, the agency said.Reuters Health Information
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Infectious Diseases News Source Type: news
More News: Arthritis | COVID-19 | European Medicines Agency (EMA) | Infectious Diseases | Orthopaedics | Rheumatoid Arthritis | Rheumatology